In Vitro Activity of Cefepime/Taniborbactam and Comparator Agents Against Gram-Negative Bacterial Bloodstream Pathogens Recovered From Patients With Cancer

Authors

Bahgat Gerges
Joel Rosenblatt
Y-Lan Truong
Ying Jiang
Samuel A Shelburne
Anne-Marie Chaftari
Ray Hachem
Issam Raad

Publication Date

4-1-2024

Journal

JAC-Antimicrobial Resistance

Abstract

BACKGROUND: Taniborbactam is a β-lactamase inhibitor that, when combined with cefepime, may offer a potential treatment option for patients with serious and resistant Gram-negative bacterial (GNB) pathogens.

OBJECTIVES: This study evaluated

METHODS: A total of 270 GNB pathogens (2019-23) isolated from patients with cancer were tested against cefepime/taniborbactam and comparator agents commonly used for these patients. CLSI-approved broth microdilution methods were used. MIC

RESULTS: Cefepime/taniborbactam showed highly potent activity against tested Enterobacterales, including isolates producing ESBLs and carbapenem-resistant Enterobacterales. At a provisional breakpoint of ≤16/4 mg/L, cefepime/taniborbactam inhibited most tested species of GNB pathogens, with overall 98.9% susceptibility, which was significantly (

CONCLUSIONS: Our results showed that taniborbactam in combination with cefepime improved

Comments

PMID: 38601790

DOI

10.1093/jacamr/dlae060

PMID

38601790

PMCID

PMC11005172

PubMedCentral® Posted Date

April 2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes